ReviewWorld journal of hepatology2016
Antiviral therapy for hepatitis C: Has anything changed for pregnant/lactating women?
Review in World journal of hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Efficacy and Safety of Antivirals in Lactating Women with Herpesviridae Infections: A Systematic Review.Viruses · 2025Pooled it
- Direct-Acting Antiviral Agents in Prevention of Maternal-Fetal Transmission of Hepatitis C Virus in Pregnancy.Pathogens (Basel, Switzerland) · 2024Review
- Hepatitis C virus eradication in people living with human immunodeficiency virus: Where are we now?World journal of hepatology · 2024Article
- The pre-conception maternal exposure to Sofosbuvir affects the mitochondrial biogenesis in prenatal fetal tissues: Experimental study on rats.Molecular medicine (Cambridge, Mass.) · 2023Article
- Prevalence and factors associated with hepatitis C among pregnant women in China: a cross-sectional study.Scientific reports · 2023Article
- Direct antiviral agents (DAAs) and their use in pregnant women with hepatitis C (HCV).Expert review of anti-infective therapy · 2022Review
- Pregnancy and fetal outcomes of chronic hepatitis C mothers with viremia in China.World journal of gastroenterology · 2022Article
- Hepatitis C Virus Infection in Pregnancy and Children: Its Implications and Treatment Considerations with Directly Acting Antivirals: A Review.JNMA; journal of the Nepal Medical Association · 2021Review
- Recommendations of the AGG (Task Force for Obstetrics, Section Maternal Diseases) on the Management of Maternal Hepatitis B, C and D Infection in Pregnancy.Geburtshilfe und Frauenheilkunde · 2021Article
- Sofosbuvir Selects for Drug-Resistant Amino Acid Variants in the Zika Virus RNA-Dependent RNA-Polymerase Complex In Vitro.International journal of molecular sciences · 2021Article
- SARS-CoV, MERS-CoV and SARS-CoV-2 infections in pregnancy and fetal development.Journal of gynecology obstetrics and human reproduction · 2020Review
- Hepatitis E virus infection during pregnancy.Virology journal · 2020Review
- Liver Disease in Pregnancy: What's New.Hepatology communications · 2020Article
- Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C.Hepatology (Baltimore, Md.) · 2020Article
- An evaluation of knowledge and concerns in women of child-bearing potential living with chronic hepatitis C infection.Canadian liver journal · 2020Article
- Hepatitis C Virus Infection in Children and Pregnant Women: An Updated Review of the Literature on Screening and Treatments.AJP reports · 2020Article
- Safety of medication use during pregnancy in mainland China: based on a national health insurance database in 2015.BMC pregnancy and childbirth · 2019Article
- Successful sofosbuvir lead-in monotherapy for the treatment of hepatitis C virus (HCV) infection in a pregnant woman living with HIV.BMJ case reports · 2019Article
- Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation - implications for maternal dosing, foetal exposure, and safety for mother and child.Alimentary pharmacology & therapeutics · 2019Review
- Opioid epidemic and liver disease.JHEP reports : innovation in hepatology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) affects about 3% of the world's population, with the highest prevalence in individuals under 40. The prevalence in pregnant women varies with geographical distribution (highest in developing countries). Prevalence also increases in sub-populations of women at high risk for blood-transmitted infections. HCV infection in pregnancy represents a non-negligible problem. However, most of the past antiviral regimens cannot be routinely offered to pregnant or breastfeeding women because of their side effects. We briefly reviewed the issue of treatment of HCV infection in pregnant/breastfeeding women focusing on the effects of the new direct-acting antivirals on fertility, pregnancy and lactation in animal studies and on the potential risk for humans based on the pharmacokinetic properties of each drug. Currently, all new therapy regimens are contraindicated in this setting because of lack of sufficient safety information and adequate measures of contraception are still routinely recommended for female patients of childbearing potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.